Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies
- PMID: 20833338
- DOI: 10.1016/j.beem.2010.03.002
Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies
Abstract
The incidence of adrenocortical tumors (ACTs) is increased in several familial cancer syndromes resulting from abnormalities in genes that encode transcription factors implicated in cell proliferation, differentiation, senescence, apoptosis, and genomic instability. These include P53, MEN1, APC, and PRKAR1A. Adenomas are the most common ACTs, but adrenocortical carcinomas occur rarely as well. The clinical manifestations of ACTs, which result from increased secretion of adrenocortical hormones, are similar in the familial and sporadic forms of the disease. However, their management may differ because of unique aspects of the constitutional syndromes. The analysis of gene expression profiles of ACTs in these constitutional syndromes have contributed to our understanding of adrenal tumorigenesis and revealed new molecular diagnostic and prognostic markers and candidate genes for targeted therapies. This chapter summarizes the clinical and biological features, pathogenesis, and management strategies for ACTs that develop in patients with familial cancer syndrome.
Copyright 2010. Published by Elsevier Ltd.
Similar articles
-
Molecular markers and the pathogenesis of adrenocortical cancer.Oncologist. 2008 May;13(5):548-61. doi: 10.1634/theoncologist.2007-0243. Oncologist. 2008. PMID: 18515740 Review.
-
Towards an understanding of the role of p53 in adrenocortical carcinogenesis.Mol Cell Endocrinol. 2012 Mar 31;351(1):101-10. doi: 10.1016/j.mce.2011.09.010. Epub 2011 Sep 10. Mol Cell Endocrinol. 2012. PMID: 21930187 Free PMC article. Review.
-
Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?Pediatr Dev Pathol. 2009 Jul-Aug;12(4):284-91. doi: 10.2350/08-06-0489.1. Pediatr Dev Pathol. 2009. PMID: 19326954
-
The molecular genetics of adrenocortical carcinoma.Rev Endocr Metab Disord. 2007 Dec;8(4):343-8. doi: 10.1007/s11154-007-9057-x. Rev Endocr Metab Disord. 2007. PMID: 17934868 Review. No abstract available.
-
[Management of adrenocortical carcinomas in children].Bull Cancer. 2011 May;98(5):595-605. doi: 10.1684/bdc.2011.1357. Bull Cancer. 2011. PMID: 21596653 Review. French.
Cited by
-
Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.Mol Cancer Res. 2022 Feb;20(2):207-216. doi: 10.1158/1541-7786.MCR-21-0583. Epub 2021 Oct 21. Mol Cancer Res. 2022. PMID: 34675114 Free PMC article.
-
Adrenocortical carcinoma and a sporadic MEN1 mutation in a 3-year-old girl: a case report.Ann Pediatr Endocrinol Metab. 2022 Dec;27(4):315-319. doi: 10.6065/apem.2142100.050. Epub 2022 Jan 17. Ann Pediatr Endocrinol Metab. 2022. PMID: 35038837 Free PMC article.
-
Prologue to the volume: Endocrine tumors and their genetics, a perspective.Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):vii-viii. doi: 10.1016/j.beem.2010.07.004. Best Pract Res Clin Endocrinol Metab. 2010. PMID: 20833328 Free PMC article. No abstract available.
-
Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.Clin Cancer Res. 2013 Apr 1;19(7):1740-7. doi: 10.1158/1078-0432.CCR-12-3354. Epub 2013 Feb 13. Clin Cancer Res. 2013. PMID: 23406775 Free PMC article.
-
Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.J Clin Oncol. 2017 Dec 10;35(35):3956-3963. doi: 10.1200/JCO.2017.74.2460. Epub 2017 Oct 23. J Clin Oncol. 2017. PMID: 29058986 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous